With two decisions originally scheduled for this week already announced, including BridgeBio's approval in ATTR-CM, the ...

ADC Therapeutics, Sutro Biopharma and Zai Lab are among those developing antibody-drug conjugates to address payload and ...

Sage Therapeutics discontinued development of its lead candidate dalzanemdor after a third clinical failure, leading analysts ...

BridgeBio secured approval for Attruby Friday, along with the all-important mortality benefit that could give the drug a ...

RFK Jr. as HHS head is perhaps President-elect Donald Trump’s most controversial Cabinet pick now that Matt Gaetz has ...

A Reuters report on Friday revealed that FDA researchers have found additional molecular evidence tying blockbuster asthma ...

The pharma is seeking full approval for its anticoagulation reversal drug Andexxa, which the FDA granted accelerated approval ...

Pending the FDA’s decision, compounding pharmacies will remain free to make and market versions of the blockbuster ...

Massachusetts’ increased investment in the life sciences industry includes boosting its life sciences tax incentive program ...

In this episode of Denatured, BioSpace's Head of Insights Lori and guests from Teva Pharmaceuticals and TOWER Capital Group ...

Novartis’ up to $1.1 billion acquisition of gene therapy specialist Kate Therapeutics fits with the pharma’s plan to expand ...

Lilly will provide the funding and expertise to advance Laekna’s LAE102, a first-in-class monoclonal antibody targeting the ...